Molecular Imaging
暂无分享,去创建一个
[1] C. Rowe,et al. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias , 2008, Molecular Neurobiology.
[2] Nelleke Tolboom,et al. Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.
[3] M. Olschewski,et al. Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows In Vivo Detection of Thrombosis and Monitoring of Thrombolysis , 2008, Circulation.
[4] Peter C M van Zijl,et al. MR tracking of transplanted cells with “positive contrast” using manganese oxide nanoparticles , 2008, Magnetic resonance in medicine.
[5] H. Soltanian-Zadeh,et al. Effects of Ferumoxides – Protamine Sulfate Labeling on Immunomodulatory Characteristics of Macrophage-like THP-1 Cells , 2008, PloS one.
[6] S. Neubauer,et al. Visualization of Activated Platelets by Targeted Magnetic Resonance Imaging Utilizing Conformation-Specific Antibodies against Glycoprotein IIb/IIIa , 2008, Journal of Vascular Research.
[7] C. Rowe,et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.
[8] G. Linazasoro,et al. IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.
[9] D. Kraitchman,et al. Imaging of stem cells using MRI , 2008, Basic Research in Cardiology.
[10] C. Bode,et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. , 2008, The Journal of clinical investigation.
[11] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[12] Markus Schwaiger,et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.
[13] S. Neubauer,et al. Magnetic Resonance Imaging of Endothelial Adhesion Molecules in Mouse Atherosclerosis Using Dual-Targeted Microparticles of Iron Oxide , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[14] H. Soltanian-Zadeh,et al. Measurement of quantity of iron in magnetically labeled cells: comparison among different UV/VIS spectrometric methods. , 2007, BioTechniques.
[15] Matthias Stuber,et al. Positive contrast visualization of iron oxide‐labeled stem cells using inversion‐recovery with ON‐resonant water suppression (IRON) , 2007, Magnetic resonance in medicine.
[16] Jurgen E Schneider,et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide , 2007, Nature Medicine.
[17] M. Ramirez-Alvarado,et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques , 2007, Journal of neurochemistry.
[18] D. Boturyn,et al. In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors , 2007, Molecular Cancer.
[19] Phillip C Yang,et al. In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides , 2007, Magnetic resonance in medicine.
[20] Samuel A Wickline,et al. Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. , 2007, Ultrasound in medicine & biology.
[21] S. DeKosky,et al. Optimal time window for standardized uptake ratio as a simplified measure of PIB retension , 2007 .
[22] B. Miller,et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.
[23] Christopher C Rowe,et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.
[24] Wolfhard Semmler,et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.
[25] J. Morris,et al. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.
[26] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[27] H. Engler,et al. In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[28] W. Heindel,et al. In vivo imaging of integrin ανβ3 expression using fluorescence-mediated tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[29] B. Miller,et al. Subtype of Mild Cognitive Impairment and Progression to Dementia and Death , 2006, Dementia and Geriatric Cognitive Disorders.
[30] Hyuing Zhang,et al. Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo , 2006, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.
[31] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[32] A. Arbab,et al. Expression of transferrin receptor and ferritin following ferumoxides–protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging , 2006, NMR in biomedicine.
[33] Z. Fayad,et al. Clearance of Iron Oxide Particles in Rat Liver: Effect of Hydrated Particle Size and Coating Material on Liver Metabolism , 2006, Investigative radiology.
[34] Paul Edison,et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.
[35] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[36] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[37] Kathryn Sharer,et al. In vivo detection of single cells by MRI , 2006, Magnetic resonance in medicine.
[38] Zahi A Fayad,et al. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T , 2006, Magnetic resonance in medicine.
[39] Antony K. Chen,et al. Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.
[40] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[42] C. Jack,et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.
[43] A. Gee,et al. Delineation of Positron Emission Tomography Imaging Agent Binding Sites on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.
[44] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[45] John M Pauly,et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles , 2005, Magnetic resonance in medicine.
[46] A. Gee,et al. Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.
[47] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[48] Ralph Weissleder,et al. Molecular imaging in the clinical arena. , 2005, JAMA.
[49] Alan P Koretsky,et al. Sizing it up: Cellular MRI using micron‐sized iron oxide particles , 2005, Magnetic resonance in medicine.
[50] Julie C Price,et al. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. , 2005, Archives of neurology.
[51] René M. Botnar,et al. Coronary magnetic resonance imaging: visualization of the vessel lumen and the vessel wall and molecular imaging of arteriothrombosis , 2005, European Radiology.
[52] Jeff W M Bulte,et al. Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.
[53] R. Moats,et al. In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.
[54] Alan A. Wilson,et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[55] Alan A. Wilson,et al. A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1) , 2004 .
[56] Heather Kalish,et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. , 2004, Blood.
[57] Ryan Park,et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. , 2004, Molecular imaging.
[58] Ralph Weissleder,et al. Seeing Within: Molecular Imaging of the Cardiovascular System , 2004, Circulation research.
[59] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[60] Susannah H Bloch,et al. Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. , 2004, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.
[61] Max A Viergever,et al. Passive tracking exploiting local signal conservation: The white marker phenomenon , 2003, Magnetic resonance in medicine.
[62] A. Kassner,et al. Molecular Imaging of Angiogenesis in Nascent Vx-2 Rabbit Tumors Using a Novel ανβ3-targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging , 2003 .
[63] Jonathan R. Lindner,et al. Imaging Tumor Angiogenesis With Contrast Ultrasound and Microbubbles Targeted to &agr;v&bgr;3 , 2003 .
[64] G. Perry,et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[65] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[66] H. Vinters,et al. Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. , 2002, Bioconjugate chemistry.
[67] B Miller,et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.
[68] R Weissleder,et al. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. , 2001, Radiology.
[69] W. Klunk,et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.
[70] J.S. Karp,et al. Application of the 3D row action maximum likelihood algorithm to clinical PET imaging , 1999, 1999 IEEE Nuclear Science Symposium. Conference Record. 1999 Nuclear Science Symposium and Medical Imaging Conference (Cat. No.99CH37019).
[71] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[72] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[73] D. Mash,et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.
[74] E. Maxwell,et al. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. , 1997, The Journal of pharmacology and experimental therapeutics.
[75] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[76] Mrc Psych,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .
[77] Arthur W. Toga,et al. A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development The International Consortium for Brain Mapping (ICBM) , 1995, NeuroImage.
[78] D. Price,et al. Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody , 1994, Journal of neuropathology and experimental neurology.
[79] D E Kuhl,et al. Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] J. Morris. The Clinical Dementia Rating (CDR) , 1993, Neurology.
[81] Karl J. Friston,et al. Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[82] T. Carlos,et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. , 1990, Blood.
[83] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[84] M. Elices,et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.
[85] D. Selkoe,et al. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.
[86] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[87] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.